The possibility of treating patients who cannot tolerate statins has long been eyed as a valuable segment of the cholesterol market, but has been a difficult claim to get past regulators. However, recent developments arguably may help build a market for what has been a hard-to-define population.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?